Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020088390 - PYRIMIDOPYRAZOLE COMPOUNDS AS FOURTH GENERATION EGFR INHIBITORS

Publication Number WO/2020/088390
Publication Date 07.05.2020
International Application No. PCT/CN2019/113608
International Filing Date 28.10.2019
IPC
C07D 403/12 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 403/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
14containing three or more hetero rings
A61K 31/506 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • 江苏先声药业有限公司 JIANGSU SIMCERE PHARMACEUTICAL CO., LTD. [CN]/[CN]
Inventors
  • 桑迎霞 SANG, Yingxia
  • 谷晓辉 GU, XiaoHui
  • 诸舜伟 ZHU, Shunwei
  • 薛黎婷 XUE, Liting
  • 于晓虹 YU, Xiaohong
  • 任晋生 REN, Jinsheng
Agents
  • 北京知元同创知识产权代理事务所(普通合伙) BEIJING ORIGINTELLIGENCE IP LAW FIRM
Priority Data
201811266972.X29.10.2018CN
201910479288.804.06.2019CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) PYRIMIDOPYRAZOLE COMPOUNDS AS FOURTH GENERATION EGFR INHIBITORS
(FR) COMPOSÉS DE PYRIMIDOPYRAZOLE UTILISÉS EN TANT QU'INHIBITEURS D'EGFR DE QUATRIÈME GÉNÉRATION
(ZH) 作为第四代EGFR抑制剂的嘧啶吡唑类化合物
Abstract
(EN)
Disclosed are novel pyrimidopyrazole compounds as fourth generation (T790M/C797S mutation) EGFR kinase inhibitors and pharmaceutical use thereof, specifically disclosed are a compound represented by formula (I), a stereoisomer, a racemate, a tautomer, an isotope label, a nitrogen oxide or a pharmaceutically acceptable salt thereof. Said compounds have good efficacy in treating diseases caused by abnormal mutation of EGFR Del19/T790M/C797S and L858R/T790M/C797S.
(FR)
L'invention concerne de nouveaux composés de pyrimidopyrazole utilisés en tant qu'inhibiteurs de kinase EGFR de quatrième génération (mutation T790M/C797S) et leur utilisation pharmaceutique. Plus particulièrement, l'invention concerne un composé représenté par la formule (I), un stéréoisomère, un racémate, un tautomère, un marqueur isotopique, un N-oxyde ou un sel pharmaceutiquement acceptable de celui-ci. Lesdits composés ont une bonne efficacité dans le traitement de maladies provoquées par une mutation anormale de L'EGFR Del19/T790M/C797S et L858R/T790M/C797S.
(ZH)
公开了第四代(T790M/C797S突变)EGFR激酶抑制剂的新型嘧啶吡唑类化合物及其医药用途,具体公开了式(I)所示化合物、其立体异构体、消旋体、互变异构体、同位素标记物、氮氧化物或其药学上可接受的盐。所述化合物在EGFR Del19/T790M/C797S和L858R/T790M/C797S异常突变引起的疾病上有着较好的疗效。(I)
Latest bibliographic data on file with the International Bureau